Immune monitoring after anti-CD19 CAR T-cel therapy with patients with B-cell NHL

Immune monitoring after anti-CD19 CAR T-cel therapy with patients with B-cell NHL - Anti-CD19 CAR T-cell therapy monitoring study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56841

Enrollment

525

Registered

2021-04-19

Start date

2021-05-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell NHL B-cell non-Hodgkin lymphoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: treatment of B-cell NHL with anti-CD19 CAR T-cel therapy

Exclusion criteria

Exclusion criteria: no informed consent

Design outcomes

Primary

Measure	Time frame
Overall objective response rate Correlation of cell free tumor DNA with ORR T-cell persistence combined with immunological and metabolic phenotype Observation of T-cell immune evasion mechanisms in tumor area	—

Secondary

Measure	Time frame
No secondary parameters	—

Countries

Netherlands

Outcome results